Related Experiment Videos
Antisense mapping KOR-1: evidence for multiple kappa analgesic mechanisms
K R Pasternak1, G C Rossi, A Zuckerman
1Department of Neurology, The George C. Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. pasterng@mskmail.mskcc.org
Brain Research
|May 4, 1999
Summary
Dynorphin B and alpha-neoendorphin show selective kappa opioid receptor binding, unlike U50,488H. Their distinct analgesic mechanisms suggest different receptor interactions, despite reversal by nor-binaltorphimine (norBNI).
Area of Science:
- Pharmacology
- Neuroscience
- Molecular Biology
Background:
- The kappa opioid receptor (KOR) system plays a crucial role in pain modulation.
- Selective ligands are essential for understanding KOR subtypes and their functions.
- Dynorphin B, alpha-neoendorphin, and U50,488H are known KOR ligands with varying affinities.
Purpose of the Study:
- To investigate the receptor selectivity and in vivo analgesic mechanisms of dynorphin B, alpha-neoendorphin, and U50,488H.
- To differentiate the KOR-1 receptor mechanisms of action for these ligands.
Main Methods:
- Binding assays were performed to determine ligand affinity for kappa opioid receptor subtypes (kappa1a and kappa1b).
- In vivo analgesic effects were assessed and reversed using the kappa1-selective antagonist nor-binaltorphimine (norBNI).
- Antisense oligodeoxynucleotides targeting KOR-1 exons were used to map receptor mechanisms.
Main Results:
- Dynorphin B and alpha-neoendorphin exhibited selectivity for the kappa1b site, whereas U50,488H bound to both kappa1a and kappa1b sites.
- All three compounds produced analgesia reversed by norBNI.
- The selectivity profiles of dynorphin B and alpha-neoendorphin analgesia against antisense probes differed significantly from U50,488H.
Conclusions:
- Dynorphin B and alpha-neoendorphin interact with the kappa opioid receptor system differently than U50,488H.
- These findings suggest distinct receptor mechanisms of action for dynorphin B and alpha-neoendorphin analgesia, despite shared kappa1 receptor involvement.